mrc

MRCT's Centre for Therapeutics Discovery has reopened their Call for Targets. They are looking for small molecule drug discovery and therapeutic antibody targets from academic researchers. (Previous applicants will have received a response from the team - if you have not yet heard regarding a previous application please contact ctd@tech.mrc.ac.uk)

CTD would like to collaborate with scientists in all universities to develop drug discovery projects targeting diseases for which there is significant unmet need. The centre will apply state of the art computational and medicinal chemistry to produce ‘drug-like’ molecules with the potential to become therapies. It will also focus on developing novel antibody therapies, bringing to bear its world-class expertise in antibody humanization technology, which has already produced two marketed therapeutic antibodies, with several more currently in clinical development.

Scientists from academia will benefit from the wealth of the CTD’s expertise including provision of tool compounds and reagents (including monoclonal antibodies) for further target validation and characterization studies, in silico screening, and access to medicinal chemistry, screening technologies and ADMET. CTD will also provide academia access to its hybridoma production capability and its extensive antibody engineering and expression expertise as well as its core antibody humanization skills. This initiative will also enable UK scientists to tap into MRC’s recently announced Developmental Pathway Funding Scheme (DPFS) and collaborate with a high quality drug discovery capability whilst retaining existing IP ownership.

If you are a researcher and wish to submit a target please visit the Call for Targets website. Alternatively, Universities and TTO's should contact read here